Difference between revisions of "Team:Pasteur Paris/Medals"

 
(37 intermediate revisions by 6 users not shown)
Line 29: Line 29:
 
}
 
}
  
−
ul li{
 
−
list-style: disc;
 
−
}
 
 
</style>
 
</style>
  
Line 69: Line 66:
 
<tr>
 
<tr>
 
<td><b>Registration and Giant Jamboree Attendance</b></td>
 
<td><b>Registration and Giant Jamboree Attendance</b></td>
−
<td>We registered for iGEM then had a great summer time. We are now waiting to attend the Giant Jamboree.</td>
+
<td>We registered for the iGEM Giant Jamboree and we can't wait to be there!</td>
 
</tr>
 
</tr>
 
<tr>
 
<tr>
 
<td><b>Competition Deliverables</b</td>
 
<td><b>Competition Deliverables</b</td>
−
<td>We plan to make the competition deliverables met on time.</td>
+
<td>We met the deadlines for every required deliverable.</td>
 
</tr>
 
</tr>
 
<tr>
 
<tr>
 
<td><b>Attributions</b</td>
 
<td><b>Attributions</b</td>
−
<td>We completed the <a href="https://2018.igem.org/Team:Pasteur_Paris/Attributions" style="font-weight: bold ; color:black; text-decoration:none;" target="_blank">attributions </a> page on our wiki.</td>
+
<td>We completed the <a href="https://2018.igem.org/Team:Pasteur_Paris/Attributions" style="font-weight: bold ; color:#85196a;"target="_blank">attributions </a> page on our wiki.</td>
 
</tr>
 
</tr>
 
<tr>
 
<tr>
 
<td><b>Characterization / Contribution</b</td>
 
<td><b>Characterization / Contribution</b</td>
−
<td>We successfully completed the <a href="https://2018.igem.org/Team:Pasteur_Paris/InterLab" style="font-weight: bold ; color:black; text-decoration:none;" target="_blank">InterLab </a> Measurement Study.</td>
+
<td>We successfully completed the <a href="https://2018.igem.org/Team:Pasteur_Paris/InterLab" style="font-weight: bold ; color:#85196a;"target="_blank">InterLab </a> Measurement Study.</td>
 
</tr>
 
</tr>
 
</table>
 
</table>
Line 102: Line 99:
 
<tr>
 
<tr>
 
<td><b>Validated Part / Validated Contribution</b></td>
 
<td><b>Validated Part / Validated Contribution</b></td>
−
<td>We created a new BioBrick part as expected : <a href="http://parts.igem.org/Part:BBa_K2616000" style="font-weight: bold ; color:black; text-decoration:none;" target="_blank">BBa_K2616000</a>. This part permits to express pro-NGF and secrete it in the extracellular medium using E. coli type I secretion system. We used inducible promoter T7, in order to control pro-NGF production thanks to IPTG induction. We also added an His-tag in N-terminal in order to purify it. pro-NGF is addressed to Type I Secretion System by fusing to it the the 60 C-terminal aminoacide of alpha-haemolysin HlyA. Since the export peptide is not processed when passing through the secretion pore, we separated pro-NGF from this 60 aminoacid long sequence by a cleaving site for TEV protease Nter-ENLYFQ-Cter. This part also permits to secrete TEV protease, under the same promoter, via this same secretion system. We succeeded in characterizing our pro-NGF by sequencing and mass spectrometry but could not purify it from the media. </td>
+
<td>We created a new BioBrick part as expected : <a href="http://parts.igem.org/Part:BBa_K2616000" style="font-weight: bold ; color:#85196a;"target="_blank">BBa_K2616000</a>. This part permits to express pro-NGF and secrete it in the extracellular medium using <i>E. coli</i> type I secretion system. Since the export peptide is not processed when passing through the secretion pore, we separated pro-NGF from this 60 aminoacid long sequence by a cleaving site for TEV protease. This part also permits to secrete TEV protease, under the same promoter, via this same secretion system. We succeeded in characterizing our pro-NGF by sequencing, Western blot, mass spectrometry and activity. </td>
 
</tr>
 
</tr>
 
<tr>
 
<tr>
 
<td><b> Collaboration </b</td>
 
<td><b> Collaboration </b</td>
 
<td>
 
<td>
−
We hosted the <a href="https://2018.igem.org/Team:Pasteur_Paris/Collaborations#MeetUp"style="font-weight: bold ; color:black; text-decoration:none;" target="_blank">4th Parisian Meet-Up </a>where we organized a Tiny Jamboree in the morning in order to practice with all the French teams for the Giant. We also organized and attended round tables about bioethics with multiples professionals during the afternoon.</br>
+
We hosted the <a href="https://2018.igem.org/Team:Pasteur_Paris/Collaborations#MeetUp"style="font-weight: bold ; color:#85196a;"target="_blank">4th Parisian Meet-up </a>where we organized a Tiny Jamboree in the morning in order to practice with all the French teams for the Giant one in October. We also organized and attended round tables about bioethics with multiple professionals during the afternoon.</br>
−
We collaborated with other iGEM teams for the Interlab (Sorbonne U Paris), by sharing and testing protocols (WPI Worcester) as well as other non-scientific collaborations. You can read about them on this <a href="https://2018.igem.org/Team:Pasteur_Paris/Collaborations" style="font-weight: bold ; color:black; text-decoration:none;" target="_blank"> page </a>.</br>
+
We collaborated with other iGEM teams for the Interlab (Sorbonne U Paris), by sharing and testing protocols (WPI Worcester) as well as other non-scientific collaborations. You can read about them on this <a href="https://2018.igem.org/Team:Pasteur_Paris/Collaborations" style="font-weight: bold ; color:#85196a;"target="_blank">page</a>.</br>
 
</td>
 
</td>
 
</tr>
 
</tr>
Line 114: Line 111:
 
<td><b>Human Practices</b</td>
 
<td><b>Human Practices</b</td>
 
<td>
 
<td>
−
We thought with care of every aspect of our project by interviewing many experts of their fields (biofilms, infections, microfluidic and prosthesis) but also associations for the right of amputees as well as surgeons and took into account their advices in our final biological interface as well as our prototype  Our juridic team has worked on the ethic and safety issues surrounding the use of GMOs inside the human body. Because we also thought about the consequence of a possible releasing of our GMOs in the environnement, we also integrated a thermosensitive Kill-Switch inside our bacteria. You can read about it on this page. </br>
+
We took into account the advice of many professionals in the conception and confinement of our interface NeuronArch. Our jurist team has worked with the Ethical Committee of the Institut Pasteur on the ethical and safety questions surrounding the use of GMOs inside the human body. They also advised us on not collecting data on persons without a proper medical supervision.  We have tried to destigmatize the use of GMOs to the general public. Because we also thought about the consequences of a possible release of our GMOs in the environment, we also integrated a thermosensitive Kill-Switch inside our bacteria. You can read about it on this <a href="https://2018.igem.org/Team:Pasteur_Paris/HP" style="font-weight: bold ; color:#85196a;"target="_blank"> page. </a> </br>
 
</td>
 
</td>
 
</tr>
 
</tr>
Line 137: Line 134:
 
<tr>
 
<tr>
 
<td><b>Integrated Human Practices</b></td>
 
<td><b>Integrated Human Practices</b></td>
−
<td>Integrated HP</td>
+
<td>We thought with care about every aspect of our project by interviewing many experts of their fields (biofilms, infections, microfluidics and prosthesis) but also associations for the right of amputees as well as surgeons and took into account their advice in our final biological interface and in our prototype. You can read about the progression of NeuronArch on this <a href="https://2018.igem.org/Team:Pasteur_Paris/Human_Practices" style="font-weight: bold ; color:#85196a;"target="_blank">page</a>.</td>.
−
</tr>
+
</tr>
 
<tr>
 
<tr>
 
<td><b>Improve a Previous Part or Project</b</td>
 
<td><b>Improve a Previous Part or Project</b</td>
−
<td></td>
+
<td> We improved the part <a href="http://parts.igem.org/Part:BBa_K237002" style="font-weight: bold ; color:#85196a;"target="_blank">BBa_K237002</a> from the iGEM team SDU Denmark 2009. We optimized the RIP sequence for our chassis <i> E. coli </i> BL21 (DE3) pLysS strain and added a secretion signal peptide to address the RIP to <i> E. coli </i> Type II Secretion System. We confirmed our part <a href="http://parts.igem.org/Part:BBa_K2616001" style="font-weight: bold ; color:#85196a;"target="_blank">BBa_K2616001</a> by sequencing. Learn more about this part on this <a href="https://2018.igem.org/Team:Pasteur_Paris/Improve" style="font-weight: bold ; color:#85196a;"target="_blank">page</a>.
 +
</td>
 
</tr>
 
</tr>
 
<tr>
 
<tr>
 
<td><b>Model Your Project</b</td>
 
<td><b>Model Your Project</b</td>
−
<td>We modelled how NGF is produced in our modified E. Coli, its diffusion in an environment and its consequences on neurons growth.  It helped to predict how to use NGF in our experiments.</td>
+
<td>We modeled how NGF is produced in our modified <i> E. coli </i>, its diffusion in a medium environment and its consequences on neurons growth.  It helped to have an insight on which concentration of NGF to use in our experiments and also helped in predicting the future growth of nerves inside of our prototype. The mechanical modeling presents tools to visualize the constraints applied on the humerus and femur bone and was used to choose the best material to use for a prosthesis and the best configuration possible for a bone. The modeling of the humerus helped us to limit the length of the osseointegrated stem. Learn more about our modeling on this <a href="https://2018.igem.org/Team:Pasteur_Paris/Model" style="font-weight: bold ; color:#85196a;"target="_blank">page</a>.  </td>
 +
</tr>
 +
<tr>
 +
<td><b>Demonstrate</b</td>
 +
<td>Our project is a made of an ambitious combination of several systems (reconnect nerves, fight infections, the kill-switch, the porous membrane, and the device). The device has been completely realized by the team, following a structured research strategy and the advice of professionals. We have also proved the expression of proNGF in <i>E. coli</i> bacteria and characterized its activity. Our kill-switch has been tested and works as expected. We also proved that our porous membrane is indeed capable of containing bacteria inside a fixed location. Finally, we have manufactured microfluidic chips to make a proof of concept of our project. Learn more about the demonstration of our project on this <a href="https://2018.igem.org/Team:Pasteur_Paris/Demonstrate" style="font-weight: bold ; color:#85196a;"target="_blank">page</a>.  </td>
 
</tr>
 
</tr>
 
</table>
 
</table>

Latest revision as of 00:34, 18 October 2018

""

Bronze medal criteria

Explanation Criteria achieved
Registration and Giant Jamboree Attendance We registered for the iGEM Giant Jamboree and we can't wait to be there!
Competition Deliverables We met the deadlines for every required deliverable.
Attributions We completed the attributions page on our wiki.
Characterization / Contribution We successfully completed the InterLab Measurement Study.

Silver medal criteria

Explanation Criteria achieved
Validated Part / Validated Contribution We created a new BioBrick part as expected : BBa_K2616000. This part permits to express pro-NGF and secrete it in the extracellular medium using E. coli type I secretion system. Since the export peptide is not processed when passing through the secretion pore, we separated pro-NGF from this 60 aminoacid long sequence by a cleaving site for TEV protease. This part also permits to secrete TEV protease, under the same promoter, via this same secretion system. We succeeded in characterizing our pro-NGF by sequencing, Western blot, mass spectrometry and activity.
Collaboration We hosted the 4th Parisian Meet-up where we organized a Tiny Jamboree in the morning in order to practice with all the French teams for the Giant one in October. We also organized and attended round tables about bioethics with multiple professionals during the afternoon.
We collaborated with other iGEM teams for the Interlab (Sorbonne U Paris), by sharing and testing protocols (WPI Worcester) as well as other non-scientific collaborations. You can read about them on this page.
Human Practices We took into account the advice of many professionals in the conception and confinement of our interface NeuronArch. Our jurist team has worked with the Ethical Committee of the Institut Pasteur on the ethical and safety questions surrounding the use of GMOs inside the human body. They also advised us on not collecting data on persons without a proper medical supervision. We have tried to destigmatize the use of GMOs to the general public. Because we also thought about the consequences of a possible release of our GMOs in the environment, we also integrated a thermosensitive Kill-Switch inside our bacteria. You can read about it on this page.

Gold medal criteria

.
Explanation Criteria achieved
Integrated Human Practices We thought with care about every aspect of our project by interviewing many experts of their fields (biofilms, infections, microfluidics and prosthesis) but also associations for the right of amputees as well as surgeons and took into account their advice in our final biological interface and in our prototype. You can read about the progression of NeuronArch on this page.
Improve a Previous Part or Project We improved the part BBa_K237002 from the iGEM team SDU Denmark 2009. We optimized the RIP sequence for our chassis E. coli BL21 (DE3) pLysS strain and added a secretion signal peptide to address the RIP to E. coli Type II Secretion System. We confirmed our part BBa_K2616001 by sequencing. Learn more about this part on this page.
Model Your Project We modeled how NGF is produced in our modified E. coli , its diffusion in a medium environment and its consequences on neurons growth. It helped to have an insight on which concentration of NGF to use in our experiments and also helped in predicting the future growth of nerves inside of our prototype. The mechanical modeling presents tools to visualize the constraints applied on the humerus and femur bone and was used to choose the best material to use for a prosthesis and the best configuration possible for a bone. The modeling of the humerus helped us to limit the length of the osseointegrated stem. Learn more about our modeling on this page.
Demonstrate Our project is a made of an ambitious combination of several systems (reconnect nerves, fight infections, the kill-switch, the porous membrane, and the device). The device has been completely realized by the team, following a structured research strategy and the advice of professionals. We have also proved the expression of proNGF in E. coli bacteria and characterized its activity. Our kill-switch has been tested and works as expected. We also proved that our porous membrane is indeed capable of containing bacteria inside a fixed location. Finally, we have manufactured microfluidic chips to make a proof of concept of our project. Learn more about the demonstration of our project on this page.